lipodystrophy


Also found in: Medical, Acronyms, Encyclopedia, Wikipedia.
Related to lipodystrophy: lipodystrophy syndrome

lipodystrophy

(ˌlɪpəʊˈdɪstrəfɪ)
n
1. (Pathology) any condition resulting in bodily loss or redistribution of fat tissue
2. (Medicine) any condition resulting in bodily loss or redistribution of fat tissue
Translations

lip·o·dys·tro·phy

n. lipodistrofia, trastorno del metabolismo de las grasas;
cephalothoracic ______ cefalotorácica;
insulin ______ insulínica;
intestinal ______ intestinal.

lipodystrophy

n lipodistrofia
References in periodicals archive ?
Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy.
in 2012, include early disease onset, recurrent febrile episodes, skin lesions--including recurrent attacks of erythematous annular plaques and violaceous swelling of the eyelids, delayed physical development, progressive lipodystrophy, arthralgias, systemic inflammation, and aseptic meningitis episodes.
The Phase IIa clinical trial will assess up to 50 patients with HIV-Associated Lipodystrophy and non-alcoholic fatty liver disease, with either AramcholTM at 600 mg or a placebo for 12 weeks.
Klein, the senior attorney and AIDS Law Project director at the Boston-based Gay & Lesbian Advocates & Defenders, had been doing appeals for lipodystrophy sufferers like Fullem.
Lipodystrophy was defined clinically by physical examination and by patient report of fat wasting in the face, arms or legs with or without central obesity.
The report provides a snapshot of the global therapeutic landscape of Lipodystrophy
Furthermore, in patients treated with cART, especially those with lipodystrophy, a gradual decrease of adiponectin levels has been noticed, coupled with a consecutive increase in cardiovascular risk.
The drug is a recombinant analogue of human leptin, indicated in the US as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Myalept is the first and only product approved in the US for the treatment of generalised lipodystrophy and it has orphan drug designation in the US, EU, and Japan.
The peroxisome proliferator-activated receptor gamma (PPARG) P465L mouse model is the equivalent human variant of partial lipodystrophy.
The causal gene, AGPAT2, which is involved in the synthesis of phosphatidic acid and triglycerides, was removed in the mice, resulting in rodents with generalized lipodystrophy.